ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AMYT Amryt Pharma PLC

14.70
0.00 (0.00%)
Last Updated: 19:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 13.45
Ask Price 15.95
News -
Company Name Stock Ticker Symbol Market Type
Amryt Pharma PLC AMYT NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 14.70 19:00:00
Open Price Low Price High Price Close Price Prev Close
14.70
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0  14.70 USD

Amryt Pharma PLC Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 940.26M - - - 9,754.35
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Amryt Pharma

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AMYT Message Board. Create One! See More Posts on AMYT Message Board See More Message Board Posts

AMYT Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).

Your Recent History

Delayed Upgrade Clock